Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical has applied for quotation on the ASX of 190,228 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The additional securities, to be quoted from 5 February 2026, represent a modest increase in the company’s listed capital base and may marginally enhance liquidity for shareholders without signaling any broader operational or strategic shift disclosed in the filing.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australian biotechnology company listed on the ASX under the code ACW, operating in the medical and life sciences sector. The company focuses on developing clinical-stage therapies, with its shares traded as ordinary fully paid securities on the Australian Securities Exchange.
Average Trading Volume: 5,972,962
Technical Sentiment Signal: Hold
Current Market Cap: A$140.4M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.